Education
About Us
Working with TipRanks
Follow Us
Nabriva Therapeutics (NBRVF)
OTHER OTC:NBRVF
| Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 35.67M | $ 27.22M | $ 5.03M | $ 7.75M | $ 6.50M |
| Gross Profit | $ 7.09M | $ 14.07M | $ 3.44M | $ 7.68M | $ 6.50M |
| Operating Income | $ -55.49M | $ -48.53M | $ -66.13M | $ -79.49M | $ -114.38M |
| EBITDA | $ -54.70M | $ -47.42M | $ -66.88M | $ -78.72M | $ -114.09M |
| Net Income | $ -57.19M | $ -49.45M | $ -69.48M | $ -82.76M | $ -114.78M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 12.41M | $ 47.67M | $ 41.38M | $ 86.19M | $ 102.23M |
| Total Assets | $ 31.77M | $ 80.91M | $ 58.44M | $ 94.11M | $ 110.42M |
| Total Debt | $ 5.22M | $ 8.03M | $ 7.73M | $ 34.50M | $ 23.72M |
| Net Debt | $ -7.19M | $ -39.63M | $ -33.63M | $ -51.52M | $ -78.28M |
| Total Liabilities | $ 28.47M | $ 27.56M | $ 25.30M | $ 52.84M | $ 41.79M |
| Stockholders' Equity | $ 3.29M | $ 53.35M | $ 33.13M | $ 41.27M | $ 68.63M |
| Cash Flow | |||||
| Free Cash Flow | $ -36.92M | $ -59.58M | $ -71.44M | $ -71.95M | $ -72.95M |
| Operating Cash Flow | $ -36.71M | $ -59.56M | $ -71.33M | $ -71.89M | $ -72.72M |
| Investing Cash Flow | $ -263.00K | $ -81.00K | $ -274.00K | $ 331.00K | $ -4.60M |
| Financing Cash Flow | $ 1.85M | $ 66.37M | $ 26.92M | $ 56.08M | $ 92.92M |
Nabriva Therapeutics Forecast EPS vs Actual EPS
Currently, no data available
Please return soon. This page is being updated.